Literature DB >> 1847346

The role of branchpoint and 3'-exon sequences in the control of balanced splicing of avian retrovirus RNA.

X D Fu1, R A Katz, A M Skalka, T Maniatis.   

Abstract

We previously described an avian sarcoma-leukosis virus (ASLV) insertion mutation that causes a decrease in the ratio of unspliced to spliced RNA in vivo, resulting in a replication defect. Pseudorevertant viruses containing cis-acting suppressor mutations that restored the normal ratio were isolated. One class of the suppressor mutations consists of single-base changes or small deletions near the 3' splice site, while another consists of deletions in the 3' exon. In this paper we report results from an in vitro analysis of wild-type, mutant, and pseudorevertant pre-mRNA splicing. We find that wild-type RNA is spliced inefficiently in vitro, and that the insertion mutation and suppressors act directly at the level of splicing. Characterization of splicing intermediates reveals that the insertion mutation and suppressor mutations located within the intron alter the pattern of lariat formation. In contrast, suppressor mutations consisting of 3' exon deletions act at an earlier step in the splicing pathway. Thus, the efficiency of splicing at the env 3' splice site can be affected at the level of spliceosome assembly, lariat formation, or cleavage at the 3' splice site and exon ligation.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 1847346     DOI: 10.1101/gad.5.2.211

Source DB:  PubMed          Journal:  Genes Dev        ISSN: 0890-9369            Impact factor:   11.361


  70 in total

1.  R region sequences in the long terminal repeat of a murine retrovirus specifically increase expression of unspliced RNAs.

Authors:  A M Trubetskoy; S A Okenquist; J Lenz
Journal:  J Virol       Date:  1999-04       Impact factor: 5.103

2.  Map of cis-acting sequences that determine alternative pre-mRNA processing in the E3 complex transcription unit of adenovirus.

Authors:  H A Brady; A Scaria; W S Wold
Journal:  J Virol       Date:  1992-10       Impact factor: 5.103

3.  Identification of cis-acting intron and exon regions in influenza virus NS1 mRNA that inhibit splicing and cause the formation of aberrantly sedimenting presplicing complexes.

Authors:  M E Nemeroff; U Utans; A Krämer; R M Krug
Journal:  Mol Cell Biol       Date:  1992-03       Impact factor: 4.272

4.  A naturally arising mutation of a potential silencer of exon splicing in human immunodeficiency virus type 1 induces dominant aberrant splicing and arrests virus production.

Authors:  M P Wentz; B E Moore; M W Cloyd; S M Berget; L A Donehower
Journal:  J Virol       Date:  1997-11       Impact factor: 5.103

5.  Cooperation of pre-mRNA sequence elements in splice site selection.

Authors:  Z Dominski; R Kole
Journal:  Mol Cell Biol       Date:  1992-05       Impact factor: 4.272

6.  Retroviral splicing suppressor sequesters a 3' splice site in a 50S aberrant splicing complex.

Authors:  Keith E Giles; Karen L Beemon
Journal:  Mol Cell Biol       Date:  2005-06       Impact factor: 4.272

7.  Serine/arginine-rich proteins contribute to negative regulator of splicing element-stimulated polyadenylation in rous sarcoma virus.

Authors:  Nicole L Maciolek; Mark T McNally
Journal:  J Virol       Date:  2007-08-01       Impact factor: 5.103

8.  The exon splicing silencer in human immunodeficiency virus type 1 Tat exon 3 is bipartite and acts early in spliceosome assembly.

Authors:  Z H Si; D Rauch; C M Stoltzfus
Journal:  Mol Cell Biol       Date:  1998-09       Impact factor: 4.272

9.  Splice site selection in polyomavirus late pre-mRNA processing.

Authors:  D B Batt; L M Rapp; G G Carmichael
Journal:  J Virol       Date:  1994-03       Impact factor: 5.103

10.  Inhibitory activity of the equine infectious anemia virus major 5' splice site in the absence of Rev.

Authors:  W Tan; M Schalling; C Zhao; M Luukkonen; M Nilsson; E M Fenyö; G N Pavlakis; S Schwartz
Journal:  J Virol       Date:  1996-06       Impact factor: 5.103

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.